Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**NotoGinseng Heart Formula** is an oral botanical dietary supplement developed by Farlong for cardiovascular health support. The product is marketed for heart support rather than as an FDA-approved therapeutic drug, and its active ingredient is a highly concentrated pharmaceutical-grade extract of *Panax notoginseng* standardized to contain high levels of saponins, including notoginsenoside and ginsenosides such as Rb1, Rg1, Rd, Re, and Rb2. Its proposed biological activity is consistent with a nutraceutical vasoprotective and cardiometabolic support product, with reported mechanisms including blood vessel relaxation, improved blood flow, and possible modulation of angiotensin-converting enzyme 2 and tumor necrosis factor-alpha pathways. It is positioned to support cardiovascular health, healthy cholesterol, blood pressure balance, and blood sugar balance, but not as an approved pharmaceutical for treatment of a specific disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NotoGinseng Heart Formula.